NCT05417750已完成1 期
An Open-label, Single-arm, Phase I Study to Evaluate the Safety and Efficacy of Autologous Tumor Infiltrating Lymphocytes Injection in Patients With Advanced Malignant Solid Tumors
Shanghai Juncell Therapeutics1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2022年10月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Maximal Tolerance Dose
研究概览
简要总结
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
The Phase I clinical trial is expected to be finished in 36 months. To be specific, the dose escalation study plans to include patients with advanced malignant solid tumors with clear pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment study plans to include those with melanoma, cervical cancer, and head and neck squamous cell tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be ≥18 and ≤75 years of age at the time of consent.
- •Patients with advanced metastatic solid tumors with clear pathological diagnosis, including melanoma, cervical cancer, head and neck squamous cell tumors, non-small cell lung cancer and breast cancer, etc.; while the expanded enrollment study plans to include those with melanoma, cervical cancer, and head and neck squamous cell tumors.
- •At least one measurable target lesion even after resection, as defined by RECIST1.
- •Lesions in previously irradiated areas (or other local therapy) should not be selected as target lesions, unless treatments was ≥3 months prior to Screening, and there has been demonstrated disease progression in that particular lesion.
- •Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Patients must have an estimated life expectancy of ≥3 months.
- •In the opinion of the Investigator, patients must be able to sign the ICF and complete all study-required procedures.
- •Patients must have the following hematologic parameters, Coagulation functions and hepatic and renal function:
- •White Blood Cell (WBC)≥2.5×10^9/L；
- •Absolute Lymphocyte Count (ANC)≥1.5×10^9/L;
- •Absolute Lymphocyte Count(ALC)≥0.7×10^9/L;
- •Platelet≥100×10^9/L；
- •International Normalized Ratio（INR）≤1.5×ULN;
- •Activated Partial Thromboplastin Time（APTT）≤1.5×ULN;
- •Serum Creatinine (Scr)≤1.5mg/dL (or 132.6μmol/L) or Creatinine Clearance≥60mL/min
- •Urinalysis: urine protein less than 2+, or 24-hour urine protein <1g;
- •Alanine aminotransferase(AST/SGOT) ≤3×ULN;
- •Alanine aminotransferase (ALT/SGPT) ≤3×ULN;
- •Total Bilirubin(TBIL)≤1.5×ULN；
- •Patients must have a washout period ≥ 4 weeks from prior anticancer therapy(ies) to the start of the planned preconditioning regimen, including targeted therapy, chemotherapy, immunotherapy: anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)/anti-PD-1, other monoclonal antibody (mAb), or vaccine Palliative radiation therapy.
- •Patients of childbearing potential or their partners of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy or fathering a child for the duration of the study and practice an approved, highly effective method of birth control during treatment and for 12 months after receiving the last protocol-related therapy.
- •Patients must have no contraindications for surgery or biopsy.
- •Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an ICF approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), and agree to abide by the study restrictions and return to the site for the required assessments, including the OS Follow-up Period.
排除标准
- •Patients have not recovered from all prior therapy-related adverse events (AEs) to ≤ Grade 1 (per Common Terminology Criteria for Adverse Events [CTCAE] v5.0), except for alopecia or vitiligo, prior to Enrollment (tumor resection).
- •Patients who have received an organ allograft or prior cell transfer therapy.
- •Patients with symptomatic and/or untreated brain metastases (of any size and any number).
- •Patients who are on chronic systemic steroid therapy for any reason.
- •Patients who have active medical illness(es) that would pose increased risk for study participation, including: active systemic infections requiring systemic ABX, coagulation disorders, or other active major medical illnesses of the cardiovascular, respiratory, or immune system.
- •Patients with systemic active infection requiring treatment, with positive blood culture or imaging evidence of infection, including active tuberculosis.
- •Patients with hepatic encephalopathy, hepatorenal syndrome, Child-Pugh class B or more severe cirrhosis, or liver failure.
- •Uncontrolled arterial hypertension（SBP≥160mmHg and/or DBP≥100mmHg）or any unstable cardiovascular or cerebrovascular disease in the recent 6 months of consent.
- •Patients who have a left ventricular ejection fraction (LVEF) < 50% or New York Heart Association (NYHA) functional classification Class 3 or Class
- •Female patients who are pregnant or breastfeeding.
- •Patients who are HIV positive, positive syphilis serological test, positive COVID-19 nucleic acid test, or clinically active hepatitis A, B, and C including virus carriers.
研究组 & 干预措施
Experimental: Cohort 1
Experimental
dose escalation group: participants with advanced solid tumors using cryopreserved GC101 TIL
干预措施: TIL therapy (Drug)
Experimental: Cohort 2
Experimental
participants with advanced malignant melanoma using cryopreserved GC101 TIL
干预措施: TIL therapy (Drug)
Experimental: Cohort 3
Experimental
participants with advanced NSCLC using cryopreserved GC101 TIL
干预措施: TIL therapy (Drug)
Experimental: Cohort 4
Experimental
participants with advanced HNSCC using cryopreserved GC101 TIL
干预措施: TIL therapy (Drug)
Experimental: Cohort 5
Experimental
participants with advanced cervical cancer using cryopreserved GC101 TIL
干预措施: TIL therapy (Drug)
结局指标
主要结局
Maximal Tolerance Dose
时间窗: Up to Day 28
Dose Limiting Toxicity
时间窗: Up to Day 28
Adverse Events
时间窗: Maximum 360 days
次要结局
- Disease Assessment for Objective Response Rate(Every 6 weeks for 12 months)
- Quality of Life Assessment(Every 6 weeks for 12 months)
- Disease Assessment for Disease Control Rate(Every 6 weeks for 12 months)
- Disease Assessment for Duration of Response(Every 6 weeks for 12 months)
- Disease Assessment for Progression-Free Survival(Every 6 weeks for 12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase Ib Study of GC101 in NSCLCNon Small Cell Lung Cancer MetastaticNon Small Cell Lung CancerNCT06473961Shanghai Juncell Therapeutics20
已完成
1 期
A Study of GC101 TIL in Advanced Melanoma (BZ)Tumor Infiltrating LymphocytesSafetyEfficacyMelanomaAdverse Drug EventNCT06120712Shanghai Juncell Therapeutics18
已完成
1 期
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active MetabolitesHealthy VolunteersNCT04149678Celgene40
招募中
早期 1 期
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid TumorsCarcinomaDigestive CancerBrain CancerGynecologic CancerHead and Neck CancerKidney CancerLung CancerMelanomaSarcomaBreast CancerNCT05961111Shanghai Yunying Medical Technology20
终止
早期 1 期
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid TumorsAdultNCT06077903Grit Biotechnology10